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Background
Asthma cost have been studied predominantly in severe
asthma and inpatient care. It is still unknown in differ-
ent levels of severity and in different regions of the
world. The aim was to estimate economic costs of
asthma treatment in specialized outpatient care in a big
city of Brazil.
Methods
Persistent asthmatics ≥ 6 years old under GINA outpati-
ent treatment were consecutively included in a real life
design and a society perspective/bottom-up approach.
They underwent routine clinical visits at 3- to 4-month
intervals and 2 interviews with 6-month intervals using
a structured instrument, made by researchers not
involved in their clinical treatment. Data on asthma
costs were collected directly from patients or parents,
regarding prior 3 to 6 months . Collected data were
valued in Brazilian Reais (R$) by using data banks from
Brazillian Ministry of Health (for public resources), Bra-
zillian Medical Association (for suplemmentary system
resources) and values informed by patients for private
resources expenditures. Exchange rate used was US$
1.00 = R$ 1.89 (purchasing power parity in 2012/World
Bank).
Results
Of 117 subjects, 108 completed the study, with female
predominance (n=79/73.8%). In initial evaluation, 16
(14.8%) had severe, 39 (36.2%) had moderate and 53
(49%) had mild asthma. Rhinitis was present in 83.3%,
and 59.2% were overweighted or obese. The majority
had elementary scholling (n=76/70.4%) and the mean
monthly family income was US$ 1,202.90 (SD=880.37),
the lowest stratum of medium economic class in Brazil.
The estimated mean asthma cost was US$ 882.37 per
patient-year (SD=717.97), corresponding to 7% of mean
annual family income (MAFI) and to 6% of per capita
gross domestic product (GDP). Estimated mean cost of
asthma plus rhinitis and associated respiratory infections
reached US$ 1,005.22 per patient-year (SD=724.07),
which corresponds to 8.3% of MAFI and 7% of per
capita GDP. The severe, not controlled, obese and over-
weight asthmatics had greater asthma costs when com-
pared to mild, controlled and normal weight ones,
(differences=449.5%, 142.7%, 51.7% and 35.6%,
respectively).
Conclusions
It is the first study describing data on associated costs of
outpatient treatment of asthma in different severity
levels in Brazil, which with think can be useful for pub-
lic health policies. The annual estimated cost represents
an important impact on family budgets and per capita
GDP. Public health strategies offering wide access to
treatment and stimulating weight reduction can contri-
bute to better results, reducing costs of asthma in Brazil.
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